Alzheimers Disease Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
This trial was a randomized, double-blind, placebo-controlled, parallel group, adaptive design with variable treatment duration planned in cognitively unimpaired participants aged 60 to 75 years, with at least one apolipoprotein E allele (APOE4), (homozygotes (HMs) or heterozygotes (HTs)) and, if HTs, with evidence of elevated brain amyloid. The participants were randomized to either CNP520 50 mg, CNP520 15 mg or placebo a 2:1:2 ratio and was stratified based on amyloid status. The planned treatment period of 5 to 8 years was not achieved due to early study termination. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02409082 -
Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures
|
N/A | |
| Terminated |
NCT02565511 -
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT01993836 -
Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care
|
Phase 4 | |
| Terminated |
NCT05097131 -
An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
|
||
| Completed |
NCT00448799 -
Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04639050 -
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05891496 -
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
|
Phase 3 | |
| Terminated |
NCT01723488 -
A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
|
Phase 0 | |
| Terminated |
NCT01733355 -
A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807
|
Phase 0 | |
| Completed |
NCT00911690 -
Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders
|
N/A | |
| Recruiting |
NCT01479855 -
Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type
|
N/A | |
| Completed |
NCT01469351 -
Identifying Potential Effects of Liraglutide on Degenerative Changes
|
N/A | |
| Completed |
NCT00439010 -
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT05269394 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01760005 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
|
Phase 2/Phase 3 | |
| Completed |
NCT04623242 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
|
Phase 2/Phase 3 | |
| Suspended |
NCT05552157 -
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
|
Phase 2/Phase 3 | |
| Completed |
NCT04023994 -
A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT01946243 -
The Feasibility of Florbetapir Quantitation
|
Phase 4 | |
| Recruiting |
NCT01642420 -
Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression
|
N/A |